Barclays raised the firm’s price target on Neurocrine to $150 from $145 and keeps an Overweight rating on the shares. The analyst remains positively biased on U.S. biopharmaceuticals into most Q4 setups, “leaning into recent winners.” The firm recommends weighting towards names with strong prescription trends, supportive guides and potential upside to 2024 numbers. It prefers Eli Lilly (LLY), Merck (MRK), AbbVie (ABBV) Regeneron (REGN). Barclays says Bristol-Myers (BMY) and Pfizer (PFE) are the “most challenged.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine director Lyons, Chief Medical Officer Roberts sell $1.3M in stock
- Neurocrine price target raised to $145 from $125 at Barclays
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- Neurocrine price target raised by $17 at Wells Fargo, here’s why
- Neurocrine initiated with neutral view at Citi, here’s why
